Karolinska Development AB (Nasdaq Stockholm: KDEV) released its Interim Report for January-June 2025. CEO Viktor Drvota emphasized a focus on patient benefit amidst market challenges. Significant events included Umecrine Cognition’s Parkinson’s research and OssDsign’s leadership change. Financially, the net loss for the quarter was SEK -73.3 million. Umecrine Cognition raised SEK 24.6 million for their clinical study.

Read more at GlobeNewswire: Interim Report – January-June 2025